SUNRISE-3：COVID-19の高リスク外来患者におけるベムニホスブビルの有効性と安全性

基本情報

NCT ID

NCT05629962

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

2,285

治験依頼者名

Atea Pharmaceuticals, Inc.

概要

The purpose of the study is to evaluate whether bemnifosbuvir (BEM) is effective and safe in adults with COVID-19 who do not need to be in the hospital but who are at high risk for progression to severe disease. Eligible subjects will be randomly assigned (by chance) to receive BEM or matching placebo orally for 5 days. Co-administration of locally available standard of care (SOC) is allowed. The total duration of the study is 60 days.

対象疾患

介入

依頼者（Sponsor）